Clinical trial · Observational
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
In Vitro Evaluation of Immune Responses in CTCL
NCT00177190CI-TRIAL-00014704completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous T-cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Mycosis Fungoides | Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
| Sezary Syndrome | Sezary Syndrome | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Functional capacity of dendritic cells in-vitro
- timeFrame
- At each cell collection
- description
- Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL)
Secondary outcomes (1)
- measure
- Evaluate antigen loading of dendritic cells
- timeFrame
- At each cell collection
- description
- Functional DCs can be isolated and effectively loaded with the malignant cells by several methods (coculture and fusion)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males or females \<18 years of age * Histologically confirmed stage IV cutaneous T-cell lymphoma, with at least 5% of the peripheral blood lymphocytes showing atypical morphology consistent with Sezary cells * Ambulatory and be in stable medical condition * Biopsy positive mycosis fungoides/CTCL or clonal type of CTCL as determined by PCR for TCR and Southern blot for TCR Exclusion Criteria: * Received any chemotherapy or radiotherapy within 4 weeks prior to enrollment * Significant psychiatric illness which would prevent adequate informed consent in the opinion of the principal investigator * Systemic steroid therapy other than maintenance for adrenal suppression * Known coagulopathy for non SS subjects.
References
Publications (0)
Data not yet available
No reference posted for this study.